In addition, we previously reported a significant relationship between PIK3CA mutations and lower pCR rate (adjusted p= 0.024) among 425 cancer‐related genes assessed by next‐generation sequencing of archived tumor blocks from 50 patients enrolled in this clinical trial.35 This evidence concerns the gene PIK3CA and cancer.